

Claudia Rossig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/408594/publications.pdf>

Version: 2024-02-01

93
papers

2,481
citations

218677

26
h-index

243625

44
g-index

98
all docs

98
docs citations

98
times ranked

3915
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. <i>Blood</i> , 2016, 127, 2101-2112.	1.4	208
2	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 884-892.	7.2	158
3	Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. <i>Blood</i> , 2015, 125, 1986-1994.	1.4	127
4	Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. <i>Oncolmmunology</i> , 2017, 6, e1250050.	4.6	86
5	Genetic Modification of T Lymphocytes for Adoptive Immunotherapy. <i>Molecular Therapy</i> , 2004, 10, 5-18.	8.2	77
6	Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 3499-3509.	7.0	76
7	EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. <i>Molecular Therapy</i> , 2019, 27, 933-946.	8.2	69
8	Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2015, 21, 4935-4946.	7.0	68
9	Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines. <i>Cancers</i> , 2020, 12, 375.	3.7	68
10	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , 2020, 10, 77.	6.2	65
11	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. <i>Leukemia</i> , 2020, 34, 151-166.	7.2	53
12	Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1312-1321.	10.7	50
13	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). <i>Blood</i> , 2021, 137, 1582-1590.	1.4	48
14	Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 823-833.	1.6	45
15	Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. <i>Oncotarget</i> , 2017, 8, 108584-108603.	1.8	42
16	FUS"DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 6227-6238.	7.0	40
17	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. <i>BMC Cancer</i> , 2019, 19, 895.	2.6	40
18	Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Cancer Immunology Research</i> , 2015, 3, 547-556.	3.4	39

#	ARTICLE	IF	CITATIONS
19	Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. <i>Nature Protocols</i> , 2016, 11, 22-36.	12.0	39
20	Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26719.	1.5	39
21	Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. <i>Haematologica</i> , 2019, 104, 120-127.	3.5	38
22	SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 3718-3731.	7.0	36
23	Control of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in Allogeneic Hematopoietic Stem Cell Transplant Recipients by a Novel Bundle Including Remodeling of Sanitary and Water Supply Systems. <i>Clinical Infectious Diseases</i> , 2017, 65, 935-942.	5.8	34
24	Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1704-1712.	1.6	33
25	First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans-retinoid acid. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26461.	1.5	32
26	Monitoring of Hematopoietic Chimerism after Transplantation for Pediatric Myelodysplastic Syndrome: Real-Time or Conventional Short Tandem Repeat PCR in Peripheral Blood or Bone Marrow?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1918-1925.	2.0	29
27	Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 513.	2.8	29
28	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. <i>Blood Advances</i> , 2021, 5, 2901-2908.	5.2	29
29	Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis. <i>Pediatric Blood and Cancer</i> , 2016, 63, 640-645.	1.5	28
30	Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 834-844.	4.1	28
31	Target Antigen Expression on a Professional Antigen-Presenting Cell Induces Superior Proliferative Antitumor T-Cell Responses via Chimeric T-Cell Receptors. <i>Journal of Immunotherapy</i> , 2006, 29, 21-31.	2.4	27
32	Aetiology of childhood acute leukaemias: current status of knowledge. <i>Radiation Protection Dosimetry</i> , 2008, 132, 114-118.	0.8	27
33	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. <i>Clinical Epigenetics</i> , 2019, 11, 188.	4.1	27
34	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	7.2	27
35	Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. <i>British Journal of Haematology</i> , 2017, 179, 272-283.	2.5	25
36	Requirement for YAP1 signaling in myxoid liposarcoma. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	25

#	ARTICLE	IF	CITATIONS
37	Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. <i>Haematologica</i> , 2018, 103, 1484-1492.	3.5	24
38	VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28313.	1.5	24
39	Response-Adapted Sequential Immuno-Chemotherapy of Post-Transplant Lymphoproliferative Disorders in Pediatric Solid Organ Transplant Recipients: Results from the Prospective Ped-PTLD 2005 Trial. <i>Blood</i> , 2014, 124, 4468-4468.	1.4	24
40	Chimeric T-Cell Receptors for the Targeting of Cancer Cells. <i>Acta Haematologica</i> , 2003, 110, 154-159.	1.4	23
41	Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory osteosarcoma (OS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11527-11527.	1.6	22
42	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	5.2	22
43	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. <i>Leukemia</i> , 2022, 36, 1516-1524.	7.2	21
44	Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. <i>Oncology Reports</i> , 2014, 32, 845-852.	2.6	20
45	Unmistakable Morphology? Infantile Malignant Osteopetrosis Resembling Juvenile Myelomonocytic Leukemia in Infants. <i>Journal of Pediatrics</i> , 2015, 167, 486-488.	1.8	20
46	GMP-Compliant Manufacturing of TRUCKS: CAR T Cells targeting GD2 and Releasing Inducible IL-18. <i>Frontiers in Immunology</i> , 2022, 13, 839783.	4.8	20
47	CAR T cell immunotherapy in hematology and beyond. <i>Clinical Immunology</i> , 2018, 186, 54-58.	3.2	19
48	Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. <i>Scientific Reports</i> , 2019, 9, 19704.	3.3	18
49	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 186.	3.5	18
50	Targeted siRNA nanocarrier: a platform technology for cancer treatment. <i>Oncogene</i> , 2022, 41, 2210-2224.	5.9	16
51	Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation. <i>Mycoses</i> , 2020, 63, 172-180.	4.0	15
52	Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1564-1575.	6.4	14
53	Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2650-2657.	7.2	13
54	Low incidence of symptomatic osteonecrosis after allogeneic <sc>HSCT</sc> in children with high-risk or relapsed <sc>ALL</sc> – results of the <sc>ALL</sc> – <sc>SCT</sc> 2003 trial. <i>British Journal of Haematology</i> , 2018, 183, 104-109.	2.5	12

#	ARTICLE	IF	CITATIONS
55	Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma. <i>Molecular Oncology</i> , 2020, 14, 248-260.	4.6	12
56	SIRP α -specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 71-83.	4.2	11
57	HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells. <i>Cancers</i> , 2021, 13, 2857.	3.7	11
58	Generation of an NF κ B-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 751138.	4.8	11
59	Cellular immunotherapy strategies for Ewing sarcoma. <i>Immunotherapy</i> , 2014, 6, 611-621.	2.0	10
60	Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial. <i>Bone Marrow Transplantation</i> , 2018, 53, 891-894.	2.4	10
61	Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 953-960.	2.5	10
62	A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study. <i>Blood</i> , 2020, 136, 8-9.	1.4	10
63	New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 539-555.	0.8	9
64	Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10-year experience at a European Pediatric Cancer Center. <i>Mycoses</i> , 2019, 62, 954-960.	4.0	9
65	Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML. <i>Blood Advances</i> , 2021, 5, 4413-4421.	5.2	9
66	Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors. <i>Nature Communications</i> , 2022, 13, 1544.	12.8	9
67	Extending the chimeric receptor-based T-cell targeting strategy to solid tumors. <i>OncImmunity</i> , 2013, 2, e26091.	4.6	8
68	Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2019, 21, e13089.	1.7	8
69	Successful Extracorporeal Life Support in a Pediatric Hematopoietic Stem Cell Transplant Recipient With Periengraftment Respiratory Failure. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e256-e259.	0.6	7
70	Titrateable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors. <i>Cancers</i> , 2021, 13, 4741.	3.7	7
71	Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2019, 134, 1294-1294.	1.4	7
72	A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study. <i>Blood</i> , 2019, 134, 2629-2629.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study.. Journal of Clinical Oncology, 2019, 37, 10031-10031.	1.6	7
74	Surface expression of the immunotherapeutic target $CD2$ in osteosarcoma depends on cell confluency. Cancer Reports, 2021, 4, e1394.	1.4	6
75	Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells. Molecular Therapy - Methods and Clinical Development, 2021, 21, 42-53.	4.1	5
76	A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol Development. Clinical Pharmacology and Therapeutics, 2021, 110, 1025-1037.	4.7	4
77	Redirecting T cells to treat solid pediatric cancers. Cancer and Metastasis Reviews, 2019, 38, 611-624.	5.9	3
78	Durable control of hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation. Journal of Viral Hepatitis, 2019, 26, 454-458.	2.0	3
79	Extracorporeal Membrane Oxygenation in Children With Cancer or Hematopoietic Cell Transplantation: Single-Center Experience in 20 Consecutive Patients. Frontiers in Oncology, 2021, 11, 664928.	2.8	3
80	High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study. Blood, 2018, 132, 1375-1375.	1.4	3
81	Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO). Blood, 2020, 136, 24-25.	1.4	2
82	Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement. Blood, 2020, 136, 1-1.	1.4	2
83	Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR). International Journal of Molecular Sciences, 2022, 23, 4920.	4.1	2
84	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. Cancers, 2022, 14, 2177.	3.7	2
85	SS18-SSX drives CREB activation in synovial sarcoma. Cellular Oncology (Dordrecht), 2022, 45, 399-413.	4.4	2
86	Immune modulation by molecular cancer targets and targeted therapies. Oncoimmunology, 2012, 1, 358-360.	4.6	1
87	Rapid Diagnosis of an AT/RT by the Detection of a Heterozygous SMARCB1 Germ Line Deletion in an Infant. Pediatric Blood and Cancer, 2016, 63, 1451-1453.	1.5	1
88	Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium. Blood, 2013, 122, 2693-2693.	1.4	1
89	Proposal of a Genetic Classifier for Risk Group Stratification in Pediatric T-Cell Lymphoblastic Lymphoma Reveals Significant Differences to T-Cell Lymphoblastic Leukemia. Blood, 2014, 124, 2398-2398.	1.4	1
90	Anti-tumor cytotoxic T lymphocytes targeting solid tumors: Ready for clinical trials. Cytotherapy, 2012, 14, 4-6.	0.7	0

#	ARTICLE	IF	CITATIONS
91	Outcome of Treatment for Relapsed Acute Lymphoblastic Leukemia in Children with Down Syndrome. Blood, 2012, 120, 669-669.	1.4	0
92	Vaccination - a Novel Strategy to Improve the Persistence of CD19CAR Transduced T-Cells in Relapsed Paediatric ALL: Preliminary Results from the CD19TPALL Study. Blood, 2014, 124, 383-383.	1.4	0
93	A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts. Blood, 2021, 138, 3836-3836.	1.4	0